311 related articles for article (PubMed ID: 12021305)
1. Disruption of transforming growth factor beta signaling by a novel ligand-dependent mechanism.
Fernandez T; Amoroso S; Sharpe S; Jones GM; Bliskovski V; Kovalchuk A; Wakefield LM; Kim SJ; Potter M; Letterio JJ
J Exp Med; 2002 May; 195(10):1247-55. PubMed ID: 12021305
[TBL] [Abstract][Full Text] [Related]
2. Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse.
Hong SW; Isono M; Chen S; Iglesias-De La Cruz MC; Han DC; Ziyadeh FN
Am J Pathol; 2001 May; 158(5):1653-63. PubMed ID: 11337363
[TBL] [Abstract][Full Text] [Related]
3. Type III TGF-beta receptor-independent signalling of TGF-beta2 via TbetaRII-B, an alternatively spliced TGF-beta type II receptor.
Rotzer D; Roth M; Lutz M; Lindemann D; Sebald W; Knaus P
EMBO J; 2001 Feb; 20(3):480-90. PubMed ID: 11157754
[TBL] [Abstract][Full Text] [Related]
4. NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-beta (transforming growth factor-beta) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-beta type I receptor.
Kuratomi G; Komuro A; Goto K; Shinozaki M; Miyazawa K; Miyazono K; Imamura T
Biochem J; 2005 Mar; 386(Pt 3):461-70. PubMed ID: 15496141
[TBL] [Abstract][Full Text] [Related]
5. Solar ultraviolet irradiation reduces collagen in photoaged human skin by blocking transforming growth factor-beta type II receptor/Smad signaling.
Quan T; He T; Kang S; Voorhees JJ; Fisher GJ
Am J Pathol; 2004 Sep; 165(3):741-51. PubMed ID: 15331399
[TBL] [Abstract][Full Text] [Related]
6. Differential responsiveness to autocrine and exogenous transforming growth factor (TGF) beta1 in cells with nonfunctional TGF-beta receptor type III.
Deng X; Bellis S; Yan Z; Friedman E
Cell Growth Differ; 1999 Jan; 10(1):11-8. PubMed ID: 9950213
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition.
Parekh TV; Gama P; Wen X; Demopoulos R; Munger JS; Carcangiu ML; Reiss M; Gold LI
Cancer Res; 2002 May; 62(10):2778-90. PubMed ID: 12019154
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor-beta induces formation of a dithiothreitol-resistant type I/Type II receptor complex in live cells.
Wells RG; Gilboa L; Sun Y; Liu X; Henis YI; Lodish HF
J Biol Chem; 1999 Feb; 274(9):5716-22. PubMed ID: 10026191
[TBL] [Abstract][Full Text] [Related]
9. Different domains regulate homomeric and heteromeric complex formation among type I and type II transforming growth factor-beta receptors.
Rechtman MM; Nakaryakov A; Shapira KE; Ehrlich M; Henis YI
J Biol Chem; 2009 Mar; 284(12):7843-52. PubMed ID: 19147499
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor beta1 receptor II is downregulated by E1A in adenovirus-infected cells.
Tarakanova VL; Wold WS
J Virol; 2003 Sep; 77(17):9324-36. PubMed ID: 12915548
[TBL] [Abstract][Full Text] [Related]
11. Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-beta (TGF-beta ) and the type II TGF-beta receptor.
Fanayan S; Firth SM; Butt AJ; Baxter RC
J Biol Chem; 2000 Dec; 275(50):39146-51. PubMed ID: 10993898
[TBL] [Abstract][Full Text] [Related]
12. Controlling long-term signaling: receptor dynamics determine attenuation and refractory behavior of the TGF-β pathway.
Vizán P; Miller DS; Gori I; Das D; Schmierer B; Hill CS
Sci Signal; 2013 Dec; 6(305):ra106. PubMed ID: 24327760
[TBL] [Abstract][Full Text] [Related]
13. Site-directed mutagenesis of the type II TGF-beta receptor indicates a ligand-binding site distinct from that of the type II activin receptor.
Guimond A; Sulea T; Pen A; Ear P; O'Connor-McCourt MD
FEBS Lett; 2002 Mar; 515(1-3):13-9. PubMed ID: 11943186
[TBL] [Abstract][Full Text] [Related]
14. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
[TBL] [Abstract][Full Text] [Related]
15. In the absence of type III receptor, the transforming growth factor (TGF)-beta type II-B receptor requires the type I receptor to bind TGF-beta2.
del Re E; Babitt JL; Pirani A; Schneyer AL; Lin HY
J Biol Chem; 2004 May; 279(21):22765-72. PubMed ID: 14996829
[TBL] [Abstract][Full Text] [Related]
16. Regulation of transforming growth factor-beta signaling.
Zhu HJ; Burgess AW
Mol Cell Biol Res Commun; 2001 Nov; 4(6):321-30. PubMed ID: 11703090
[TBL] [Abstract][Full Text] [Related]
17. TGF-β sensitivity is determined by N-linked glycosylation of the type II TGF-β receptor.
Kim YW; Park J; Lee HJ; Lee SY; Kim SJ
Biochem J; 2012 Aug; 445(3):403-11. PubMed ID: 22571197
[TBL] [Abstract][Full Text] [Related]
18. SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells.
Francki A; McClure TD; Brekken RA; Motamed K; Murri C; Wang T; Sage EH
J Cell Biochem; 2004 Apr; 91(5):915-25. PubMed ID: 15034927
[TBL] [Abstract][Full Text] [Related]
19. A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition.
Yang J; Dai C; Liu Y
J Am Soc Nephrol; 2005 Jan; 16(1):68-78. PubMed ID: 15537870
[TBL] [Abstract][Full Text] [Related]
20. Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II.
Guerrero-Esteo M; Sanchez-Elsner T; Letamendia A; Bernabeu C
J Biol Chem; 2002 Aug; 277(32):29197-209. PubMed ID: 12015308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
